Skip to main content

Table 1 Features of the Population under Study

From: Compounded glycopyrrolate is a compelling choice for drooling children: five years of facility experience

Number of patients (%)

21 (100)

Sex, number (%)

 Male

14 (66.7)

 Female

7 (33.3)

Age (median range)

12 (2–19)

 Primary pathology, number (%)

 Cerebral palsy

7 (33,3)

 Encephalopathy

5 (23,8)

 Suprabulbar paralysis

1 (4,8)

 SMA

2 (9,5)

 Herpetic encephalitis

1 (4,8)

 Generalized dyspraxia

1 (4,8)

 Anorexia

1 (4,8)

 Genetic syndromes

3 (14,3)

Gross Motor Function Classification System, number (%)

 GMFCS I

0 (0)

 GMFCS II

2 (9,5)

 GMFCS III

2 (9,5)

 GMFCS IV

6 (23,9)

 GMFCS V

11 (57,1)

PPI administration, number (%)

 Yes

13 (61,9)

 No

8 (39,1)

PEG, number (%)

 Yes

10 (47,6)

 No

11 (52,4)

Fundoplication, number (%)

 Yes

6 (28,6)

 No

15 (71,4)

Tracheostomy, number (%)

 Yes

4 (19)

 No

17 (81)

Current scopolamine therapy, number (%)

 Yes

2 (9,5)

 No

19 (90,5)

Antiepileptic treatment, number (%)

 Yes

13 (61,9)

 No

8 (39,1)

Other drugs, number (%)

 Yes

15 (71,4)

 No

6 (28,6)

Past therapies for drooling, number (%)

 Scopolamine

3 (14,3)

 Botulinum toxin

5 (23,8)

  1. PPI Proton pump inhibitors, PEG Percutaneous endoscopic gastrostomy